Sugi Predict

Sugi Predict / Compounds / SCHEMBL2171472

SCHEMBL2171472

SCHEMBL2171472

COC(=O)CCCc1nc2cc(N(CCCl)CCCl)ccc2n1C

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC6 Q9UBN7 7/20 0.79
▸ HDAC1 Q13547 4/20 0.79
▸ HDAC3 O15379 2/20 0.79
▸ HDAC4 P56524 2/20 0.79
▸ HDAC2 Q92769 2/20 0.79
▸ HDAC8 Q9BY41 2/20 0.79
▸ HDAC5 Q9UQL6 2/20 0.79
▸ PTGS1 P23219 1/20 0.79
▸ HDAC10 Q969S8 1/20 0.79
▸ MEN1 O00255 1/20 0.41
▸ RECQL P46063 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ ALDH1A1 P00352 3/20 0.39
▸ PKM P14618 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ PDE3B Q13370 3/20 0.39
▸ PDE3A Q14432 3/20 0.39
▸ PDE2A O00408 2/20 0.39
▸ P2RY12 Q9H244 2/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9966133 0.92 HDAC6 (0.79) HDAC6HDAC1HDAC3HDAC4HDAC2
SCHEMBL15104883 0.91 HDAC6 (0.64) HDAC6HDAC1HDAC3HDAC4HDAC2
SCHEMBL29406239 0.90 HDAC6 (0.76) HDAC6HDAC1HDAC3HDAC4HDAC2
SCHEMBL229510 0.90 HDAC6 (0.76) HDAC6HDAC1HDAC3HDAC4HDAC2
SCHEMBL2019945 0.89 HDAC6 (0.74) HDAC6HDAC1HDAC3HDAC4HDAC2
Hydrochloric Acid SCHEMBL2781680 0.89 HDAC6 (0.74) HDAC6HDAC1HDAC3HDAC4HDAC2
Bendamustine SCHEMBL26319 0.88 HDAC6 (1.00) HDAC6HDAC1HDAC3HDAC4HDAC2
SCHEMBL12400943 0.88 HDAC6 (0.84) HDAC6HDAC1HDAC3HDAC4HDAC2
Bendamustine SCHEMBL9950832 0.88 HDAC6 (1.00) HDAC6HDAC1HDAC3HDAC4HDAC2
Bendamustine SCHEMBL29394147 0.88 HDAC6 (1.00) HDAC6HDAC1HDAC3HDAC4HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109422695-B Preparation method of bendamustine hydrochloride crude product 扬子江药业集团有限公司 2022-03-18 — — CN claimed
US-20240075014-A1 STABLE PHARMACEUTICAL COMPOSITIONS OF BENDAMUSTINE SLAYBACK PHARMA LLC (US) 2024-03-07 — — US disclosed
US-11826466-B2 Bendamustine solution formulations NAVINTA, LLC (US) 2023-11-28 — — US disclosed
US-11826466-B2 Bendamustine solution formulations NAVINTA, LLC (US) 2023-11-28 — — US disclosed
US-20230310384-A1 STABLE PHARMACEUTICAL COMPOSITIONS OF BENDAMUSTINE SLAYBACK PHARMA LLC (US) 2023-10-05 — — US disclosed
US-11707450-B1 Stable pharmaceutical compositions of bendamustine SLAYBACK PHARMA LLC (US) 2023-07-25 — — US disclosed
CN-109422695-B Preparation method of bendamustine hydrochloride crude product 扬子江药业集团有限公司 2022-03-18 — — CN disclosed
CN-109422695-B Preparation method of bendamustine hydrochloride crude product 扬子江药业集团有限公司 2022-03-18 — — CN disclosed
US-20210169798-A1 Bendamustine Solution Formulations PROVIDENT BANK 2021-06-10 — — US disclosed
US-10905677-B2 Bendamustine solution formulations NAVINTA, LLC (US) 2021-02-02 — — US disclosed
US-8420829-B2 Processes for the preparation of bendamustine CEPHALON, INC. (US) 2013-04-16 — — US disclosed
US-8420829-B2 Processes for the preparation of bendamustine CEPHALON, INC. (US) 2013-04-16 — — US disclosed
US-8420829-B2 Processes for the preparation of bendamustine CEPHALON, INC. (US) 2013-04-16 — — US disclosed
US-20110190509-A1 Processes for the Preparation of Bendamustine CEPHALON, INC. (US) 2011-08-04 — — US disclosed
US-20110190509-A1 Processes for the Preparation of Bendamustine CEPHALON, INC. (US) 2011-08-04 — — US disclosed
US-20110190509-A1 Processes for the Preparation of Bendamustine CEPHALON, INC. (US) 2011-08-04 — — US disclosed
EP-2346836-A1 PROCESSES FOR THE PREPARATION OF BENDAMUSTINE Cephalon, Inc. (US) 2011-07-27 — — EP disclosed
WO-2011079193-A2 PREPARATION OF BENDAMUSTINE AND ITS SALTS DR. REDDY'S LABORATORIES LTD. (IN) 2011-06-30 — — WO disclosed
WO-2010042568-A1 PROCESSES FOR THE PREPARATION OF BENDAMUSTINE CEPHALON, INC. (US) 2010-04-15 — — WO disclosed
WO-2010042568-A1 PROCESSES FOR THE PREPARATION OF BENDAMUSTINE CEPHALON, INC. (US) 2010-04-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11826466-B2 Bendamustine solution formulations BHMT, BHMT2, BAD HDAC6 1244/4885HDAC1 1909/4885HDAC3 3451/4885
US-20230310384-A1 STABLE PHARMACEUTICAL COMPOSITIONS OF BENDAMUSTINE SORD, NONO, SBDS HDAC6 1384/4885HDAC1 3398/4885HDAC3 3707/4885
US-11707450-B1 Stable pharmaceutical compositions of bendamustine SORD, NONO, SBDS HDAC6 1270/4885HDAC1 3593/4885HDAC3 3810/4885
US-20110190509-A1 Processes for the Preparation of Bendamustine THPO, FOLR1, FOLR2 HDAC6 2878/4885HDAC1 4641/4885HDAC3 4686/4885
US-20210169798-A1 Bendamustine Solution Formulations BHMT, BHMT2, BAD HDAC6 1244/4885HDAC1 1909/4885HDAC3 3451/4885
US-20240075014-A1 STABLE PHARMACEUTICAL COMPOSITIONS OF BENDAMUSTINE SORD, NONO, SBDS HDAC6 1384/4885HDAC1 3398/4885HDAC3 3707/4885
US-10905677-B2 Bendamustine solution formulations BHMT, MET, BHMT2 HDAC6 194/4885HDAC1 1004/4885HDAC3 2348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.